4//SEC Filing
Berrey M Michelle 4
Accession 0001104659-22-009551
CIK 0001270073other
Filed
Jan 30, 7:00 PM ET
Accepted
Jan 31, 4:13 PM ET
Size
7.7 KB
Accession
0001104659-22-009551
Insider Transaction Report
Form 4
Berrey M Michelle
President, R&D and CMO
Transactions
- Award
Common Stock
2022-01-27+10,300→ 77,418 total - Award
Option to Purchase Common Stock
2022-01-27+17,600→ 17,600 totalExercise: $14.44Exp: 2032-01-27→ Common Stock (17,600 underlying)
Footnotes (2)
- [F1]Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2022.
- [F2]The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2022.
Documents
Issuer
INTERCEPT PHARMACEUTICALS, INC.
CIK 0001270073
Entity typeother
Related Parties
1- filerCIK 0001397329
Filing Metadata
- Form type
- 4
- Filed
- Jan 30, 7:00 PM ET
- Accepted
- Jan 31, 4:13 PM ET
- Size
- 7.7 KB